Working… Menu

Treatment of SARS Caused by COVID-19 With Ruxolitinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04334044
Recruitment Status : Recruiting
First Posted : April 3, 2020
Last Update Posted : February 2, 2021
Information provided by (Responsible Party):
Grupo Cooperativo de Hemopatías Malignas

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 1, 2021
Estimated Study Completion Date : May 1, 2021